Treatment with mifepristone results in clinically meaningful improvements in HbA1c and cardiometabolic risk in patients with difficult-to-control T2D and hypercortisolism. Medscape Diabetes & Endocrinology
Treatment with mifepristone results in clinically meaningful improvements in HbA1c and cardiometabolic risk in patients with difficult-to-control T2D and hypercortisolism. Medscape Diabetes & Endocrinology